Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Br J Dermatol. 2015 Jun 19;173(3):671–680. doi: 10.1111/bjd.13829

Table 2.

Clinical characteristics and molecular screening results of melanomas and associated nevi

CASE BRAF NRAS CKIT PPP6C STK19 RAC1 LOCAL SUBTYPE BRESLOW CLARK type of nevus
1 WT A,B,* WT A,B,# WT A,B WT A,B WT A,B WT A,B HEAD N/S 0.7 III N/A
2 V600E A,B,* WT A,B WT A,B WT A,B WT A,B WT A,B TRUNK N/S 1.25 III N/A
3 V600E A,B,* WT A,B WT A,B WT A,B WT A,B WT A,B TRUNK N/S IS I N/A
4 WT A,B,* WTA,#,Q61KB,# WT A,B WT A,B WT A,B WT A,B HEAD SSM 0.45 III N/A
5 WT A,B,* WT A,B WT A,B WT A,B WT A,B WT A,B EXT N/S IS I N/A
6 N/AA,V600EB,* N/AA,WTB N/AA,WTB N/AA,WTB N/AA,WTB N/AA,WTB EXT NM 2.5 III junctional
7 V600EA,WTB WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK N/S IS I N/A
8 WT A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK N/S IS I N/A
9 WT A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK N/S IS I junctional
10 WT A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B N/A SSM 0.8 III N/A
11 WT A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK N/S IS I compound
12 WT A,B* WT A,B WT A,B WT A,B WT A,B WT A,B TRUNK SSM 1.15 III N/A
13 WT A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK N/S IS I compound
14 WTA,V600EB* WT A,B,# WT A,B WT A,B WT A,B WT A,B N/A SSM 0.4 II junctional
15 V600E A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.4 II N/A
16 V600E A,B* Q61KA,#, WTB,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.5 II compound
17 V600E A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B EXT SSM 0.35 II N/A
18 WT A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.75 III compound
19 V600E A,B* WT A,B WT A,B WT A,B WT A,B WT A,B TRUNK N/S IS I intradermal
20 WT A,B* WT A,B WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.7 III compound
21 WT A,B* WT A,B WT A,B WT A,B WT A,B WT A,B TRUNK N/S IS I compound
22 WT A,B* WT A,B WT A,B WT A,B WT A,B WT A,B EXT N/S IS I junctional
23 V600E A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B EXT N/S IS I congenital
24 V600E A,B* WTA,#,Q61KB,# WT A,B WT A,B WT A,B WT A,B EXT N/S IS I junctional
25 V600E A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B N/A SSM 0.45 II junctional
26 V600EA,WTB WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.5 II compound
27 V600EA*,WTB* WT A,B,# WT A,B WT A,B WT A,B WT A,B EXT N/S IS I N/A
28 WTA*,V600EB* WT A,B WT A,B WT A,B WT A,B WT A,B N/A N/S IS I N/A
29 V600EA*,WTB* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM IS I N/A
30 WTA*,V600EB* WTA,#,Q61KB,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.5 II N/A
31 WT A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM IS I compound
32 WTA*,V600EB* WTA,#,Q61KB,# WT A,B WT A,B WT A,B WT A,B EXT SSM IS I N/A
33 WT A,B* Q61K A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK N/S IS I compound
34 V600E A,B* WT A,B WT A,B WT A,B WT A,B WT A,B EXT SSM 0.45 II compound
35 V600E A,B* Q61K A,B,# WT A,B WT A,B WT A,B WT A,B EXT SSM 0.5 III N/A
36 WT A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B N/A N/A N/A N/A N/A
37 V600E A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.52 III N/A
38 V600EA*,WTB* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.6 III N/A
39 V600E A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM IS I N/A
40 WT A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 1.01 IV N/A
41 V600E A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.8 III congenital
42 V600EA*,WTB* WTA,#,Q61KB,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.7 III N/A
43 WT A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.5 III N/A
44 V600EA*,WTB* WT A,B,# WT A,B WT A,B WT A,B WT A,B N/A SSM 0.7 IV N/A
45 WT A,B* WTA,#,Q61KB,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM IS I congenital
46 WT A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B EXT SSM 0.3 II N/A
47 V600EA*,WTB* Q70H/Q61K A,#, Q61KB,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.9 III N/A
48 WTA*,V600EB* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.8 III congenital
49 WT A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B EXT SSM 1.2 IV intradermal
50 V600E A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B ACRAL ACRAL LENTIGINOUS 1.3 IV intradermal
51 WT A,B* WT A,B WT A,B WT A,B WT A,B WT A,B TRUNK SSM 1.2 IV N/A
52 WT A,B* Q61K A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.5 II N/A
53 V600E A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B N/A SSM 0.85 III N/A
54 V600E A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 0.6 III congenital
55 V600E A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B EXT SSM 1 III N/A
56 V600E A,B* Q61KA,#, WTB,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 1.4 III N/A
57 V600E A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B N/A SSM 0.55 I N/A
58 WT A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B EXT SSM 0.5 II N/A
59 V600E A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B EXT N/A N/A N/A N/A
60 V600E A,B* WT A,B,# WT A,B WT A,B WT A,B WT A,B TRUNK SSM 1.2 IV congenital
61 V600E A,B* D33D/Q61KA,#, WTB,# WT A,B WT A,B WT A,B WT A,B ACRAL N/S IS I N/A

N/A: not available; N/S: not specified

A

Nevus result;

B

Melanoma result; EXT: extremities; SSM: superficial spreading melanoma; IS: in situ melanoma;

*

Result determined by Sanger sequencing and V600E allele-specific fluorescent PCR;

#

Result determined by Sanger sequencing and SNaPshot method.